MIM
HLVX

MetLife Investment Management’s HilleVax HLVX Stock Holding History

MetLife Investment Management’s Portfolio HLVX Stock Details HLVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-17,118
Closed -$248K – 2865
2024
Q2 		$248K Buy
17,118
+2,723
+19% +$37.4K ﹤0.01% 2116
2024
Q1 		$239K Hold
14,395
– – ﹤0.01% 2092
2023
Q4 		$231K Buy
14,395
+2,830
+24% +$37.6K ﹤0.01% 2161
2023
Q3 		$156K Hold
11,565
– – ﹤0.01% 2338
2023
Q2 		$199K Buy
11,565
+2,860
+33% +$44.3K ﹤0.01% 2282
2023
Q1 		$144K Buy
8,705
+667
+8% +$10.7K ﹤0.01% 2397
2022
Q4 		$134K Hold
8,038
– – ﹤0.01% 2469
2022
Q3 		$137K Buy
+8,038
New +$117K ﹤0.01% 2516

Other funds holding HLVX

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

MetLife Investment Management's HLVX Position: Q3 2024 in Review

MetLife Investment Management sold out of HilleVax (HLVX) in Q3 2024, closing a stake of 17,118 shares — an estimated $248K sold.

MetLife Investment Management first reported a position in HLVX in Q3 2022 and held it in 8 quarters. The position peaked at $248K in Q2 2024. 79 funds tracked by Wall St. Rank hold HLVX as of Q3 2024.

  • MetLife Investment Management reported no remaining HilleVax position as of Q3 2024 after selling out during the quarter.
  • MetLife Investment Management sold 17,118 HilleVax shares in Q3 2024, an estimated $248K.
  • MetLife Investment Management first reported a position in HilleVax in Q3 2022 and held it in 8 quarters.
  • MetLife Investment Management's HilleVax position peaked at $248K in Q2 2024.
  • 79 funds tracked by Wall St. Rank held HilleVax as of Q3 2024.

Based on MetLife Investment Management's 13F filing for Q3 2024, filed 13 Nov 2024.